Health Trials

About this trial

This study will evaluate the effect of intravenous injection of umbilical cord tissue derived mesenchymal stem cells (UMSCs) on the improvement of renal function in patients with chronic kidney disease (CKD) at stage 3 or 4, with the change of estimated glomerular filtration rate (eGFR) as the primary endpoint, and other changes in renal function laboratory indicators, changes in other organ system function laboratory indicators, and adverse reaction events as secondary endpoints. This trial aims to further evaluate the efficacy and safety of UMCSs in CKD patients, and provide new insights into expanding the clinical treatment strategies, delaying the progression and improving the prognosis of CKD patients.

Eligibility criteria

Qualifiers

Agreement to participate in the trial and provision of signed written informed consent

Pathological diagnosis of diabetic nephropathy or hypertensive renal damage

15 ≤ eGFR < 60 mL/min/1.73m², UACR > 300 mg/g

Age ≥ 18 years

Disqualifiers

Extremely severe anemia (hemoglobin < 30 g/L)

Received blood product transfusion therapy within 1 month

Autosomal dominant or recessive polycystic kidney disease (ADPKD)

History of kidney transplant or other solid organ transplant

Trial design

Treatments tested in this trial

  • 0.9% sodium chloride
  • MSCs

Treatment groups

32 Participants
are divided into 4 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

The First Affiliated Hospital of Air Force Medicial University

Lead sponsor

Source ClinicalTrials.gov